Esophageal Reflux Clinical Trial
Official title:
Esophagoprotection by Rabeprazole Mediated by Restoration of an Impairment in Esophageal Mucin Production: Its Potential Therapeutic Benefit in Patients With Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to determine the production of mucin in GERD/RE subjects before and after 8 weeks of treatment with rabeprazole.
Enrolled patients will undergo collection of salivary and esophageal secretions. Subsequently, all patients will receive rabeprazole (20mg QD) for 8 weeks and will be re-endoscoped to confirm complete healing of reflux esophagitis. In patients with completely healed reflux esophagitis the second collection of salivary and esophageal secretion will be implemented. In both secretions, adequately coded for the laboratory Research Fellow (blinded in terms of which sample is collected before and which after treatment with rabeprazole) the content of mucin will be measured using commercially available assay and its secretion expressed in units per minute of collection time. ;
Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01260935 -
Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures
|
N/A | |
| Completed |
NCT01601379 -
Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.
|
Phase 4 | |
| Not yet recruiting |
NCT03183310 -
The Effect of Chlorpromazine on Esophageal Sensitivity in Healthy Volunteers.
|
N/A | |
| Completed |
NCT00634608 -
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
|
N/A | |
| Completed |
NCT03375060 -
Histology Post-Endoscopic Eradication Therapy (EET)
|
N/A |